Oncolytic virotherapy for cancer treatment: Challenges and solutions

Journal of Gene Medicine

Volumn 7, Issue 11, 2005, Pages 1380-1389

  Davis, J J ^a   Fang, B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenovirus; Herpes virus; Measles virus; Oncolytic virus; p53; PKR; Rb; Virotherapy

Indexed keywords

ADHZ3; ADP53RC; ANTINEOPLASTIC AGENT; AXDADB 3; CRE RECOMBINASE; CV 787; CV 890; DL 1331; E1A PROTEIN; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LIPOSOME; MACROGOL; NDV 73 T; NDV PV 701; ONCOLYTIC VIRUS; ONYX 015; ONYX 320; ONYX 411; PROTEIN KINASE R; RAS PROTEIN; RECOMBINANT DNA; RETINOBLASTOMA PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TETRACYCLINE; THYMIDINE KINASE; TRANSCRIPTION FACTOR E2F; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ADENOVIRUS 5; B LYMPHOCYTE; CANCER THERAPY; CLINICAL TRIAL; CYTOTOXICITY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; ENCAPSULATION; GALLBLADDER CANCER; GENE TECHNOLOGY; HUMAN; INNATE IMMUNITY; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SUICIDE GENE; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIROTHERAPY; VIRUS CHARACTERIZATION; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; HUMANS; IMMUNE SYSTEM; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS (GENETICS); RAS PROTEINS; VIRAL PROTEINS;

ADENOVIRIDAE; HERPESVIRIDAE; HUMAN ADENOVIRUS TYPE 5; MEASLES VIRUS; NEWCASTLE DISEASE VIRUS; ONYX; POXVIRIDAE;

EID: 27944497796     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.800     Document Type: Review

References (93)

1. American Cancer Society. American Cancer Facts and Figures 2002, 2003.
2. Douek M, Taylor I. Good practice and quality assurance in surgical oncology. Lancet Oncol 2003; 4: 626-630.
3. Farassati F, Yang AD, Lee PWK. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001; 3: 745-750.
4. Imperiale MJ, Kao HT, Feldman LT, Nevins JR, Strickland S. Common control of the heat-shock gene and early adenovirus genes - evidence for a cellular E1A-like activity. Mol Cell Biol 1984; 4: 867-874.
5. Dobner T, Horikoshi N, Rubenwolf S, Shenk T. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science 1996; 272: 1470-1473.
6. Heise C, SampsonJohannes A, Williams A, McCormick F, VonHoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639-645.
7. Nemunaitis J, et al. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther 2003; 10: 341-352.
8. McCormick F. Cancer specific viruses and the development of ONYX-015. Cancer Biol Ther 2003; 2: S157-S160.
9. Reid T, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070-6079.
10. Hann B, Balmain A. Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants. J Virol 2003; 77: 11 588-11 595.
11. Fueyo J, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12.
12. Lamfers MLM, et al. Potential of the conditionally replicative adenovirus Ad5-Delta 24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002; 62: 5736-5742.
13. Portella G, et al. ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 2003; 88: 5027-5032.
14. Fukuda K. et al. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. Cancer Res 2003; 63: 4434-4440.
15. Johnson L, et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002; 1: 325-337.
16. Zhao T, et al. Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo. Cancer Res 2003; 63: 3073-3078.
17. Steinwaerder DS, Carlson CA, Lieber A. DNA replication of first-generation adenovirus vectors in tumor cells. Hum Gene Ther 2000; 11: 1933-1948.
18. Steinwaerder DS, Carlson CA, Otto DL, Li ZY, Ni SH, Lieber A. Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector. Nat Med 2001; 7: 240-243.
19. Zeh HJ, Bartlett DL. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther 2002; 9: 1001-1012.
20. Cascallo M. Capella G. Mazo A, Alemany R. Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res 2003; 63: 5544-5550.
21. Bergmann M, et al. A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res 2001; 61: 8188-8193.
22. Liu BL, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003; 10: 292-303.
23. Wheelock EF, Dingle JH. Observations on the repeated administration of viruses to a patient with acute leukemia. A preliminary report. N Engl J Med 1964; 271: 645-651.
24. Lichty BD, et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther 2004; 15: 821-831.
25. Stojdl DF, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821-825.
26. Balachandran S, Porosnicu M. Barber GN. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol 2001; 75: 3474-3479.
27. Asada T. Treatment of human cancer with mumps virus. Cancer 1974; 34: 1907-1928.
28. Okuno Y, et al. Studies on the use of mumps virus for treatment of human cancer. Biken J 1978; 21: 37-49.
29. Csatary LK, et al. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 1993; 17: 619-627.
30. Cassel WA, Garrett RE. Newcastle disease virus as an antineoplastic agent. Cancer 1965; 18: 863-868.
31. Pecora AL, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002; 20: 2251-2266.
32. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332-1334.
33. Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci U S A 2004; 101: 11 099-11 104.
34. Grote D, et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001; 97: 3746-3754.
35. Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet 1971; 2: 105-106.
36. Reichard KW, et al. Newcastle disease virus selectively kills human tumor cells. J Surg Res 1992; 52: 448-453.
37. Fernandez M, Porosnicu M, Markovic D, Barber GN. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 2002; 76: 895-904.
38. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002; 62: 4656-4662.
39. Peng KW, Donovan KA, Schneider U, Cattaneo R, Lust JA, Russell SJ. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood 2003; 101: 2557-2562.
40. Hammond AL, Plemper RK, Zhang J, Schneider U, Russell SJ, Cattaneo R. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol 2001; 75: 2087-2096.
41. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci U S A 2000; 97: 6803-6808.
42. Nagai Y. Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Rev Med Virol 1999; 9: 83-99.
43. Roner MR. Rescue systems for dsRNA viruses of higher organisms. Adv Virus Res 1999; 53: 355-367.
44. Russell SJ. RNA viruses as virotherapy agents. Cancer Gene Ther 2002; 9: 961-966.
45. Yu DC, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61: 517-525.
46. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1. antigen. J Clin Invest 2000; 106: 763-771.
47. Takahashi M, et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther 2002; 5: 627-634.
48. Wirth T, et al. A telomerase dependent conditionally replicating adenovirus for treatment of hepatocellular carcinoma. J Hepatol 2003; 38: 214-215.
49. Li Y, et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 2001; 61: 6428-6436.
50. Wirth T, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 2003; 63: 3181-3188.
51. Huang TG, Savontaus MJ, Shinozaki K, Sauter BV, Woo SLC. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther 2003; 10: 1241-1247.
52. Fechner H, et al. A novel tetracycline-controlled transactivator-transrepressor system enables external control of oncolytic adenovirus replication. Gene Ther 2003; 10: 1680-1690.
53. Hemminki A, et al. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther 2003; 7: 163-173.
54. Bauzon M, Castro D, Karr M, Hawkins LK, Hermiston TW. Multigene expression from a replicating adenovirus using native viral promoters. Mol Ther 2003; 7: 526-534.
55. Sauthoff H, et al. Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum Gene Ther 2002; 13: 1859-1871.
56. Fu X, Meng F, Tao L, Jin A, Zhang X. A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus. Gene Ther 2003; 10: 1458-1464.
57. Gahery-Segard H, et al. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol 1998; 72: 2388-2397.
58. Harvey BG, McKinney RL, Rosengart T, Lesser ML, Crystal RG. Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. Mol Ther 2002; 6: 287-297.
59. Yen N, et al. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type P53 (Ad-p53). Cancer Gene Ther 2000; 7: 530-536.
60. Raper SE, et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002; 13: 163-175.
61. Mickelson CA. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther 2002; 13: 3-13.
62. Neff-LaFord HD, Vorderstrasse BA, Lawrence BP. Fewer CTL, not enhanced NK cells, are sufficient for viral clearance from the lungs of immunocompromised mice. Cell Immunol 2003; 226: 54-64.
63. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996; 8: 271-280.
64. Ochsenbein AF, et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 1999; 96: 2233-2238.
65. Cheng F, Gabrilovich D, Sotomayor EM. Immune tolerance in breast cancer. Breast Dis 2004; 20: 93-103.
66. Asemissen AM, et al. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104). Clin Cancer Res 2005; 11: 290-297.
67. Ioannides CG, Platsoucas CD, Freedman RS. Immunological effects of tumor vaccines: II. T cell responses directed against cellular antigens in the viral oncolysates. In Vivo 1990; 4: 17-24.
68. Stevenson FK, et al. DNA vaccines to attack cancer. Proc Natl Acad Sci U S A 2004; 101 (Suppl 2): 14646-14652.
69. Wodarz D. Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res 2001; 61: 3501-3507.
70. Palomba ML, et al. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Cancer Res 2005; 11: 370-379.
71. Hallden G, et al. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther 2003; 8: 412-424.
72. Wang Y, et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 2003; 21: 1328-1335.
73. Yotnda P, et al. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther 2002; 5: 233-241.
74. Croyle MA, Chirmule N, Zhang Y, Wilson JM. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 2001; 75: 4792-4801.
75. O'Riordan CR, et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 1999; 10: 1349-1358.
76. Siemens DR, et al. Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol 2001; 166: 731-735.
77. Bouvet M, et al. Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther 1998; 5: 189-195.
78. Masri MA. The mosaic of immunosuppressive drugs. Mol Immunol 2003; 39: 1073-1077.
79. MacDonald AS. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. Transplant Proc 2003; 35: 201S-208S.
80. Mirani M, Elenkov I, Volpi S, Hiroi N, Chrousos GP, Kino T. HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection. J Immunol 2002; 169: 6361-6368.
81. Efrat S, Fejer G, Brownlee M, Horwitz MS. Prolonged survival of pancreatic islet allografts mediated by adenovirus immunoregulatory transgenes. Proc Natl Acad Sci U S A 1995; 92: 6947-6951.
82. Lichtenstein DL, Toth K, Doronin K, Tollefson AE, Wold WS. Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol 2004; 23: 75-111.
83. Doronin K, Toth K, Kuppuswamy M, Krajcsi P, Tollefson AE, Wold WS. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 2003; 305: 378-387.
84. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 1996; 14: 1574-1578.
85. Watkins SJ, Mesyanzhinov VV, Kurochkina LP, Hawkins RE. The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther 1997; 4: 1004-1012.
86. Dmitriev I, Kashentseva E, Rogers BE, Krasnykh V, Curiel DT. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol 2000; 74: 6875-6884.
87. Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. Biochim Biophys Acta 2002; 1575: 1-14.
88. Hemminki A, Dmitriev I, Liu B, Desmond RA, Alemany R, Curiel DT. Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res 2001; 61: 6377-6381.
89. Vigne E, Mahfouz I, Dedieu JF, Brie A, Perricaudet M, Yeh P. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol 1999; 73: 5156-5161.
90. Fueyo J, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003; 95: 652-660.
91. Wu H, et al. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther 2002; 13: 1647-1653.
92. Flowers CC, Woffendin C, Petryniak J, Yang S, Nabel GJ. Inhibition of recombinant human immunodeficiency virus type 1 replication by a site-specific recombinase. J Virol 1997; 71: 2685-2692.
93. Smythe WR, et al. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 1994; 54: 2055-2059.